Perioperative Allogenenic Blood Transfusion Is Associated With Worse Clinical Outcome For Patients Undergoing Gastric Carcinoma Surgery A Meta-Analysis

Whether perioperative allogenic blood transfusion (ABT) has adverse effect on patients with gastric carcinoma (GC) surgery or not, that is controversial. Our study evaluated the association between ABT and some clinical outcomes of GC surgery patients.Data of relevant studies were based on PubMed, EMBASE, and the Cochrane Library search. The relative risk (RR) of 5-year survival rates, tumor recurrence, and postoperative complications were performed; subgroup analyses included district, transfusion rates, age, participants, sex, and tumor stage.The study was approved by the ethics committee of the First People's Hospital of Shunde.In total, 9189 participants from 16 studies were included in the meta-analysis. The 5-year survival rate was decreased for the GC patients with ABT (RR=0.74, 95% confidence interval [CI]=0.69-0.79), the risk of tumor recurrence was significantly higher for ABT patients (RR=1.82, 95% CI=1.32-2.51), and postoperative complications increased in ABT patients (RR=1.36, 95% CI=1.02-1.81), respectively; in subgroup analyses, 5-year survival rates were not associated with the transfusion rates ((2)=0.37, P=0.54).Transfusion for patients undergoing GC surgery, even low transfusion rates, would reduce the 5-year survival rates, and elevated the risk of tumor recurrence and postoperative complication.